US Puma Biotechnology (Nasdaq: PBYI) announced that investigators presented results from the neratinib arm of the Phase II Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT Trial) at the 2021 Society for Neuro-Oncology Annual Meeting.
Although preliminary results did not achieve the primary endpoint, subgroup analyses demonstrated improved PFS in patients with EGFR activation and a non-significant trend toward improved overall survival in patients with EGFRVIII mutations. However, this is essentially another disappointmeneratinibnt in the search for a glioblastoma treatment.
Neratinib is already approved in the USA under the brand name Nerlynx for the treatment of various breast cancers.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze